Dickkopf-1: a suitable target for the management of myeloma bone disease

Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

(2009) Y.-W. Qiang et al.   BLOOD

Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice

(2009) Maya Kansara et al.   JOURNAL OF CLINICAL INVESTIGATION

Wnt signaling: A win for bone

(2008) Elke Piters et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

(2008) Y.-W. Qiang et al.   BLOOD

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

(2008) Y.-W. Qiang et al.   BLOOD

The role of Dickkopf-1 in bone development, homeostasis, and disease

(2008) J. J. Pinzone et al.   BLOOD

Osteoimmunology: Interactions of the Bone and Immune System

(2008) Joseph Lorenzo et al.   ENDOCRINE REVIEWS

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma

(2008) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

(2008) Deborah J Heath et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

(2008) E Terpos et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

(2007) Ya-Wei Qiang et al.   BONE